Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-04-26
2011-04-26
Chandrakumar, Nizal S (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07932389
ABSTRACT:
The present invention is related to octahydropyrrolo[2,3,c]pyridine derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.
REFERENCES:
patent: 00 44730 (2000-08-01), None
patent: 01 83461 (2001-08-01), None
patent: 02 070521 (2002-09-01), None
patent: 03 016248 (2003-02-01), None
Elizabeth Ambrose Amin, et al., “Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Models for a Novel Class of Piperazine-Based Stromelysin-1 (MMP-3) Inhibitors: Applying a “Divide and Conquer” Strategy”, Journal of Medicinal Chemistry, vol. 44, No. 23, XP 002309081, pp. 3849-3855, 2001.
M. G. Belvisi, et al., “The Role of Matrix Metalloproteinases (MMPs) in the Pathophysiology of Chronic Obstructive Pulmonary Disease (COPD): A Therapeutic role for inhibitors of MMPs?”, Inflammation Research, vol. 52, pp. 95-100, 2003.
O. Bulbena, et al., “Cytoprotective Activity in the Gastric Mucosa of Rats Exposed to Carbon Tetrachloride-Induced Liver Injury”, Inflammation, vol. 21, No. 5, pp. 475-488, 1997.
Ian M Clark, et al., “Metalloproteinases: Their Role in Arthritis and Potential as Therapeutic Targets”, Expert Opinion Therapeutic Patents, vol. 7, No. 1, pp. 19-34, 2003.
Terence M Doherty, et al., “Therapeutic Developments in Matrix Metalloproteinase Inhibition”, Expert Opinion Therapeutic Patents, vol. 12, No. 5, pp. 665-707, 2002.
Barbara Fingleton, “Matrix Metalloproteinase Inhibitors for Cancer Therapy: The Current Situation and Future Prospects”, Expert Opinion Therapeutic Patents, vol. 7, No. 3, pp. 385-397, 2003.
Michael H. Fisher, et al., “A Convenient Synthesis of 6-Azaindole”, J. Heterocycl. Chem., vol, 6, pp. 775-776, 1969.
Zorina S. Galis, et al., “Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis the Good, the Bad, and the Ugly”, Circulation Research, vol. 90, pp. 251-262, 2002.
Y Henrotin, et al., “The Inhibition of Metalloproteinases to Treat Osteoarthritis: Reality and New Perspectives”, Expert Opinion Therapeutic Patents, vol. 12, No. 1, pp. 29-43, 2002.
Nigel M. Hooper, et al., “Membrane Protein Secretases”, Biochem. J., vol. 321, pp. 265-279, 1997.
Solveig Horstmann, et al.,“Profiles of Matrix Metalloproteinases, Their Inhibitors, and Laminin in Stroke Patients. Influence of Different Therapies”, Stroke, vol. 34, No. 9, pp. 2165-2170, 2003.
Ingman T., et al., “Matrix Metalloproteinases and Their Inhibitors in Gingival Crevicular Fluid and Saliva of Periodontitis Patients”, Journal of Clinical Periodontology, vol. 23, pp. 1127-1132, 1996.
Ganesh Krishna, et al., “New Therapies of Chronic Obstructive Pulmonary Disease”, Expert Opinion Investig. Drugs, vol. 13, No. 3, pp. 255-267, 2004.
David Leppert, et al., “Matrix Metalloproteinases: Multifunctional Effectors of Inflammation in Multiple Sclerosis and Bacterial Meningitis”, Brain Research Reviews, vol. 36, pp. 249-257, 2001.
Ghislain Opdenakker, et al., “Functional Roles and Therapeutic Targeting of Gelatinase B and Chemokines in Multiple Sclerosis”, The Lancet Neurology, vol. 2, pp. 747-756, 2003.
J. Thomas Peterson, “Matrix Metalloproteinase Inhibitor Development and the Remodeling of Drug Discovery”, Heart Failure Reviews, vol. 9, pp. 63-79, 2004.
Jerry W. Skiles, et al., “The design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors”, Current Medicinal Chemistry, vol. 8, pp. 425-474, 2001.
Jerauld S Skotnicki, et al., “Design Strategies for the Indentification of MMP-13 and Tace Inhibitors”, Current Opinion in Drug Discovery and Development, vol. 6, No. 5, pp. 742-759, 2003.
Robert Visse, et al., “Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases. Structure, Function, and Biochemistry”, Circulation Research, vol. 92, pp. 827-839, 2003.
Catharina M. P. Vos, et al., “Matrix Metalloproteinase-12 is Expressed in Phagocytotic Macrophages in Active Multiple Sclerosis Lesions”, Journal of Neuroimmunology, vol. 138, pp. 106-114, 2003.
Carol K. Wada, et al., “Phenoxyphenyl Sulfone N-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors”, Journal of Medicinal Chemistry, vol. 45, No. 1, pp. 219-232, 2002.
C. Graham Knight, et al., “A Novel Coumarin-Labelled Peptide for Sensitive Continuous Assays of the Matrix Metalloproteinases”., FEBS Letters, vol. 296, No. 3, pp. 263-266, 1992.
Bombrun Agnes
Swinnen Dominique
Chandrakumar Nizal S
Merck Serono S.A.
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
Octahydropyrrolo[2,3C]pyridine derivatives and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Octahydropyrrolo[2,3C]pyridine derivatives and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Octahydropyrrolo[2,3C]pyridine derivatives and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2697833